We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.
- Authors
Citrin, Deborah E.; Prasanna, Pataje G. S.; Walker, Amanda J.; Freeman, Michael L.; Eke, Iris; Barcellos-Hoff, Mary Helen; Arankalayil, Molykutty J.; Cohen, Eric P.; Wilkins, Ruth C.; Ahmed, Mansoor M.; Anscher, Mitchell S.; Movsas, Benjamin; Buchsbaum, Jeffrey C.; Mendonca, Marc S.; Wynn, Thomas A.; Coleman, C. Norman
- Abstract
A workshop entitled 'Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate' (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.
- Subjects
RADIATION-induced abnormalities; ONCOLOGY research; CANCER research; NATIONAL Cancer Institute (U.S.); RADIOBIOLOGY; UNIVERSITIES &; colleges
- Publication
Radiation Research, 2017, Vol 188, Issue 1, p1
- ISSN
0033-7587
- Publication type
Article
- DOI
10.1667/RR14784.1